Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RN7SK pseudogene 181 (RN7SKP181) is annotated as a pseudogene related to the RN7SK small nuclear RNA gene, which is a noncoding RNA that plays critical roles in controlling the elongation phase of transcription by regulating the activity of positive transcription elongation factor b (P-TEFb)[1][2][3][4]. However, pseudogenes such as RN7SKP181 do **not** produce functional RNA involved in these regulatory processes and are generally considered transcriptionally inactive remnants of their parent genes. There is no evidence that RN7SKP181 functions as a receptor, enzyme, transporter, transcription factor, or any canonical therapeutic target. The functional RN7SK is evolutionarily conserved and involved in transcriptional control, cell cycle regulation, and neuron development, but these activities do **not** extend to its pseudogenes[1][2][3][4][5]. The designation "pseudogene" indicates that RN7SKP181 is **not** a therapeutic target and does **not** have established biological functions, disease roles, drug interactions, mechanisms of action, or safety information relevant to targeting.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RN7SK pseudogene 181 (RN7SKP181).